

ADURO BIOTECH, INC.

Form 4

April 22, 2015

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Rogers John E. and Lois A.

(Last) (First) (Middle)

C/O ADURO BIOTECH, INC., 626  
BANCROFT WAY, 3C

(Street)

BERKELEY, CA 94710

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol

ADURO BIOTECH, INC. [ADRO]

3. Date of Earliest Transaction  
(Month/Day/Year)

04/20/2015

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2015		C		14,400	A	11 28,308
Common Stock	04/20/2015		C		543,988	A	11 572,296
Common Stock	04/20/2015		C		2,193,460	A	11 2,765,756
Common Stock	04/20/2015		C		2,847,774	A	11 5,613,530
Common Stock	04/20/2015		C		231,171	A	11 5,844,701

Edgar Filing: ADURO BIOTECH, INC. - Form 4

Common Stock	04/20/2015	P	147,058	A	\$ 17	5,991,759	D	
Common Stock	04/20/2015	C	37,898	A	<u>(1)</u>	37,898	I	By Buchholz Rogers Family Living Trust 2012 <sup>(2)</sup>
Common Stock	04/20/2015	C	14,400	A	<u>(1)</u>	52,298	I	By Buchholz Rogers Family Living Trust 2012 <sup>(2)</sup>
Common Stock	04/20/2015	C	18,949	A	<u>(1)</u>	18,949	I	By Christopher Hagerman <sup>(3)</sup>
Common Stock	04/20/2015	C	7,200	A	<u>(1)</u>	26,149	I	By Christopher Hagerman <sup>(3)</sup>
Common Stock	04/20/2015	C	37,898	A	<u>(1)</u>	37,898	I	By Phan Rogers Trust <sup>(4)</sup>
Common Stock	04/20/2015	C	14,400	A	<u>(1)</u>	52,298	I	By Phan Rogers Trust <sup>(4)</sup>
Common Stock	04/20/2015	C	18,949	A	<u>(1)</u>	18,949	I	By Joseph Rogers <sup>(5)</sup>
Common Stock	04/20/2015	C	7,200	A	<u>(1)</u>	26,149	I	By Joseph Rogers <sup>(5)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount Underlying Security (Instr. 3 and 4)
---	---	---	---	---	---	--	--

Edgar Filing: ADURO BIOTECH, INC. - Form 4

	Security		Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	A N S
	Series A Preferred Stock	(1)	04/20/2015	C		14,400	(1)	(1)	Common Stock	
	Series A-1 Preferred Stock	(1)	04/20/2015	C		543,988	(1)	(1)	Common Stock	
	Series B Preferred Stock	(1)	04/20/2015	C		2,193,460	(1)	(1)	Common Stock	2
	Series C Preferred Stock	(1)	04/20/2015	C		2,847,774	(1)	(1)	Common Stock	2
	Series D Preferred Stock	(1)	04/20/2015	C		231,171	(1)	(1)	Common Stock	
	Series B Preferred Stock Warrant (right to buy) <sup>(6)</sup>	\$ 1.1937	04/20/2015	D <sup>(6)</sup>		11,815	04/15/2011	04/15/2016	Series B Preferred Stock	
	Common Stock Warrant (right to buy) <sup>(6)</sup>	\$ 1.66	04/20/2015	A <sup>(6)</sup>	8,506		04/15/2011	04/15/2016	Common Stock	
	Series C Preferred Stock	(1)	04/20/2015	C		37,898	(1)	(1)	Common Stock	
	Series D Preferred Stock	(1)	04/20/2015	C		14,400	(1)	(1)	Common Stock	
	Series C Preferred Stock	(1)	04/20/2015	C		18,949	(1)	(1)	Common Stock	

Series D Preferred Stock	<u>(1)</u>	04/20/2015	C	7,200	<u>(1)</u>	<u>(1)</u>	Common Stock
Series C Preferred Stock	<u>(1)</u>	04/20/2015	C	37,898	<u>(1)</u>	<u>(1)</u>	Common Stock
Series D Preferred Stock	<u>(1)</u>	04/20/2015	C	14,400	<u>(1)</u>	<u>(1)</u>	Common Stock
Series C Preferred Stock	<u>(1)</u>	04/20/2015	C	18,949	<u>(1)</u>	<u>(1)</u>	Common Stock
Series D Preferred Stock	<u>(1)</u>	04/20/2015	C	7,200	<u>(1)</u>	<u>(1)</u>	Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Rogers John E. and Lois A. C/O ADURO BIOTECH, INC. 626 BANCROFT WAY, 3C BERKELEY, CA 94710			X	

## Signatures

/s/ Jennifer Lew,  
Attorney-in-Fact

04/22/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into 0.72 of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.
- (1) Preferred Stock automatically converted into 0.72 of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.
  - (2) The securities are held by Buchholz Rogers Family Living Trust 2012, over which John E. Rogers exercises voting control.
  - (3) The securities are held by Christopher Hagerman, over which John E. Rogers exercises voting control.
  - (4) The securities are held by Phan Rogers Trust, over which John E. Rogers exercises voting control.
  - (5) The securities are held by Joseph Rogers, over which John E. Rogers exercises voting control.
  - (6) Pursuant to the terms of the Series B Preferred Stock Warrant (the "Old Warrant"), effective upon conversion of all outstanding shares of Series B Preferred Stock of the Issuer, the Old Warrant converts into a Warrant to purchase shares of Common Stock of the Issuer (the "New Warrant"). The two transactions reported in Table II above show the cancellation of the Old Warrant and acquisition of the New

## Edgar Filing: ADURO BIOTECH, INC. - Form 4

Warrant in connection with the automatic conversion of the Series B Preferred Stock into 0.72 of a share of common stock immediately prior to the closing of the Issuer's initial public offering.

### Remarks:

This is the first of two Forms 4 filed by the reporting person on the same date, April 22, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.